ZORBA Weight Loss Supplement (Q-Slim) Leads To A Promising New, Second Generation, Anti-Cholesterol Drug Candidate To Lower Cholesterol And Raise HDL (Good Cholesterol)

Early preliminary results for the ZPRO Pharmaceutical, Inc. weight-loss supplement fiber Q-Slim (non-exclusive sale license recently granted to ZORBA Nutraceuticals, Inc., see November 30, 2005 press release, http://www.prweb.com/releases/2005/11/prweb315974.htm) has led to a second generation, very promising, new prescription drug candidate. This candidate will now undergo further testing and seek FDA approval as a drug for lowering cholesterol and triglyceride levels, while raising good cholesterol (HDL) levels. Supplemental data from weight loss studies comparing Q-Slim to CortiSlim and placebo control groups, surprising showed that participants taking the Q-Slim supplement had lower cholesterol and lower triglycerides levels, while raising their HDL cholesterol (good cholesterol) levels. This confirmed that a second generation, more powerful composition known as Compound Z is also likely to perform well as an anti-cholesterol FDA drug candidate. A 90 day human study (double blind, where neither study providers nor study participants know what they are taking) with Q-Slim is expected to conclude during late December 2005.

(PRWEB) December 11, 2005 -- While ZPRO cautioned ZORBA and others that early study data are still limited and preliminary, the early results for the Q-Slim human study are both very exciting and promising for second generation, more powerful compositions that are founded upon the Q-Slim technology. At the beginning and at the end of the 90 day weight loss study, participants also took a blood test to determine blood levels of total cholesterol, LDL cholesterol (bad cholesterol), HDL cholesterol (good cholesterol) and triglycerides (fat blood).

Participants taking Q-Slim were observed to have significantly lowered cholesterol, lowered LDL, lowered triglycerides (blood fat) levels, and elevated HDL (good cholesterol) levels. In fact, some participants on Q-Slim that started the study with normal and average HDL levels even moved into the higher range of HDL levels that are classified as “protective against heart disease” by the American Heart Association, and some participants in the “danger” levels were move up out of the danger range into the better normal and average HDL level range.

Q-Slim is a weight loss supplement formulated from natural fibers and nutrients, which is a powerful, new and innovative (“first of its kind”) all-natural component technology fat sponge. While Q-Slim fiber human study data shows promising results for using Q-Slim as a formulation for a non-prescription supplement fiber to promote heart health and assist with weight loss, the more exciting aspects of these results are the suggestions of even greater promise for future modifications. Second generation fibers designed from concepts learned from the basic Q-Slim technology are expected to provide great drug candidates for FDA approval in the area of anti-cholesterol drugs.

ZORBA has learned that ZPRO scientists have stepped up the research pace for a new drug candidate (Compound Z), which is expected to move beyond proof of concept testing and seriously begin pre-clinical FDA testing next year. As discussed above, this second generation composition will utilize information that has been learned from Q-Slim dietary supplement fiber studies. While the Compound Z drug candidate that will undergo FDA studies is a different composition (different chemical structure) than Q-Slim fibers, it preserves and utilizes concepts learned from Q-Slim research.

Unlike Q-Slim fibers, Compound Z has a greatly enhanced ability to bind to bile salts in the digestive system. Compound Z is expected to maintain many of the properties observed for Q-Slim (lowering total cholesterol while raising good cholesterol, HDL), but is designed for a different market than weight loss. Compound Z is expected to be far more powerful (many orders of magnitude more powerful) than Q-Slim in lowering total cholesterol. Since Compound Z incorporates the ability to remove large amounts of bile salts from the digestive system, it depletes stored excess cholesterol that is used to manufacture new bile salts in the liver.

Bile salts (that help digest fats as calories) are ordinarily recycled by the body (by the bowel and liver), but binding digestive bile salts and removing them from the digestive system forces the body to use up stored cholesterol to make more bile salts. Compound Z is a novel compound, which is drug candidate expected to cause even greater reductions of cholesterol levels than the supplement Q-Slim does, while preserving the ability of Q-Slim fibers to raise HDL levels.

Compound Z will be a non-systemic FDA drug candidate (a formulation that does its work only in the digestive system). Compound Z is ultimately expected to be approved as the only prescription formulation on the market with such abilities in a single multi-faceted compound (non-systemic). No single FDA approved product is currently reported to be able to significantly lower total cholesterol while simultaneously raising good cholesterol (HDL) levels. Compound Z is expected to have much less effectiveness in binding dietary fat and promoting weight loss than the supplement Q-Slim fiber.

Modifications and improvements in Compound Z structures (compared to Q-Slim supplements) are expected to dramatically increase the ability of Compound Z to remove bile salts and further lower cholesterol levels as compared to Q-Slim. No side negative side effects are expected for Compound Z at the anticipated dosage. Should Compound Z live up to its early promise, it will be a powerful new formulation that could render obsolete (for many people) the use of systemic cholesterol production inhibitors (statins) that often have undesirable side effects. Even persons on statin drugs may be able to cut back on the amount of statin required to maintain a desirable cholesterol level, if they take Compound Z along with their statin dosage.

Q-Slim is a trademark of ZPRO Pharmaceutical, Inc.

The above statements are based upon analysis of data or opinions obtained by the author, and they have not been evaluated by the Food and Drug Administration. Q-Slim is not intended to diagnose, treat or cure any disease. Consult with your doctor before starting any weight loss program. See the www.azorba.com website for more information.

###